Get started
Crinetics Pharmaceuticals, Inc.Crinetics Pharmaceuticals, Inc.Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CRNX chart


Full chart

CRNX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.33 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.77 USD
Net income (FY)
‪−214.53 M‬ USD
Revenue (FY)
‪4.01 M‬ USD
Shares float
‪84.62 M‬
Beta (1Y)
1.96

Employees


Employees (FY)
290
Change (1Y)
+80 +38.10%
Revenue / Employee (1Y)
‪13.84 K‬ USD
Net income / Employee (1Y)
‪−739.76 K‬ USD

About Crinetics Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Scott R. Struthers
Headquarters
San Diego
Website
crinetics.com
Founded
2008
FIGI
BBG00BC59224
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CRNX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CRNX is 59.95 USD — it has increased by 1.10% in the past 24 hours. Watch Crinetics Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Crinetics Pharmaceuticals, Inc. stocks are traded under the ticker CRNX.
CRNX stock has risen by 8.04% compared to the previous week, the month change is a 15.02% rise, over the last year Crinetics Pharmaceuticals, Inc. has showed a 108.30% increase.
We've gathered analysts' opinions on Crinetics Pharmaceuticals, Inc. future price: according to them, CRNX price has a max estimate of 97.00 USD and a min estimate of 48.00 USD. Watch CRNX chart and read a more detailed Crinetics Pharmaceuticals, Inc. stock forecast: see what analysts think of Crinetics Pharmaceuticals, Inc. and suggest that you do with its stocks.
CRNX reached its all-time high on Oct 22, 2024 with the price of 60.04 USD, and its all-time low was 10.63 USD and was reached on Mar 17, 2020. View more price dynamics on CRNX chart.
See other stocks reaching their highest and lowest prices.
CRNX stock is 2.20% volatile and has beta coefficient of 1.96. Track Crinetics Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Crinetics Pharmaceuticals, Inc. there?
Today Crinetics Pharmaceuticals, Inc. has the market capitalization of ‪5.39 B‬, it has decreased by −5.07% over the last week.
Yes, you can track Crinetics Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Crinetics Pharmaceuticals, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
CRNX earnings for the last quarter are −0.94 USD per share, whereas the estimation was −0.86 USD resulting in a −9.44% surprise. The estimated earnings for the next quarter are −0.91 USD per share. See more details about Crinetics Pharmaceuticals, Inc. earnings.
Crinetics Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪399.00 K‬ USD, despite the estimated figure of ‪467.27 K‬ USD. In the next quarter, revenue is expected to reach ‪218.09 K‬ USD.
CRNX net income for the last quarter is ‪−74.06 M‬ USD, while the quarter before that showed ‪−66.93 M‬ USD of net income which accounts for −10.65% change. Track more Crinetics Pharmaceuticals, Inc. financial stats to get the full picture.
No, CRNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 290.00 employees. See our rating of the largest employees — is Crinetics Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Crinetics Pharmaceuticals, Inc. EBITDA is ‪−277.57 M‬ USD, and current EBITDA margin is ‪−5.52 K‬%. See more stats in Crinetics Pharmaceuticals, Inc. financial statements.
Like other stocks, CRNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Crinetics Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Crinetics Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Crinetics Pharmaceuticals, Inc. stock shows the strong buy signal. See more of Crinetics Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.